BioSpecifics Technologies Corp. (BSTC:NASDAQ) Investor Relations Material

Overview

BioSpecifics Technologies Corp. is a biopharmaceutical company that is focused on the development of injectable collagenase clostridium histolyticum, which has multiple indications in the United States. The company's XIAFLEX and XIAPEX brands offer treatment for Dupuytren’s contracture and Peyronie’s disease in various countries such as Canada, Australia, Brazil, Mexico, and Europe.

Annual Reports

Frequently Asked Questions

What is BioSpecifics Technologies Corp.'s ticker?

BioSpecifics Technologies Corp.'s ticker is BSTC

What exchange is BioSpecifics Technologies Corp. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are BioSpecifics Technologies Corp.'s headquarters?

They are based in Lynbrook, New York

How many employees does BioSpecifics Technologies Corp. have?

There are 1-10 employees working at BioSpecifics Technologies Corp.

What is BioSpecifics Technologies Corp.'s website?

It is http://www.biospecifics.com/

What type of sector is BioSpecifics Technologies Corp.?

BioSpecifics Technologies Corp. is in the Healthcare sector

What type of industry is BioSpecifics Technologies Corp.?

BioSpecifics Technologies Corp. is in the Biotechnology industry

Who are BioSpecifics Technologies Corp.'s peers and competitors?

The following five companies are BioSpecifics Technologies Corp.'s industry peers:

- Forward Pharma A/S

- Nyrada

- ImmuCell

- Orchard Therapeutics plc

- NextCure